Truist analyst Robyn Karnauskas raised the firm’s price target on Immunovant (IMVT) to $48 from $30 and keeps a Buy rating on the shares. The analyst cites the firm’s increased conviction in the opportunity with FcRn given that the FcRn class revenue opportunity is “vast and growing”, with 22 indications in clinic. With argenx SE (ARGX) as a comp, Immunovant shares appear “undervalued”, Truist tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant to Present at Upcoming Investor Conferences
- Immunovant price target raised to $51 from $50 at Citi
- Immunovant files automatic mixed securities shelf
- Immunovant reports Q2 EPS (45c), consensus (47c)
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023